{"schema_version":"secwatch.filing_event.v1","accession":"0001828318-23-000198","form_type":"8-K","ticker":"ENVX","cik":"0001828318","company_name":"Enovix Corp","filed_at":"2023-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.807080+00:00","generated_at":"2026-06-10T05:36:59.745151+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enovix cuts workforce by 185; shifts Fab1 from manufacturing to R&D; misses Q3 cell production guidance","bullets":["Workforce reduction of ~185 personnel (including over 125 contractors) with restructuring charge of ~$2.5M.","Accelerated depreciation of $36M for Gen1 equipment in Q4 2023–Q1 2024; annualized savings of $22M from restructuring.","Q3 2023 small cell production cut to 24,000 units vs. guidance of 36,000; expected Q3 revenue only ~$0.2M.","Fab1 becomes 'Center for Innovation' for R&D; high-volume manufacturing to shift to Asia.","Strategy pivots from standard cells to custom cells for large customers like smartphone OEMs and U.S. Army."],"urls":{"canonical":"https://secwatch.observer/filing/0001828318-23-000198","json":"https://secwatch.observer/filing/0001828318-23-000198.json","markdown":"https://secwatch.observer/filing/0001828318-23-000198.md","text":"https://secwatch.observer/filing/0001828318-23-000198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828318/000182831823000198/0001828318-23-000198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828318/000182831823000198/envx-20231003.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T05:36:59.745151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c98c3ab65ccfd6783299016e687c2514c864af51","claim":"Enovix Corp reported third quarter of 2023 results: revenue approximately $200,000 of total revenue.","evidence_excerpt":"Enovix did produce enough custom cells in the third quarter, primarily for the U.S. Army program, that it expects to recognize approximately $200,000 of total revenue.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828318/000182831823000198/0001828318-23-000198-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Revenue","value":"approximately $200,000 of total revenue"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}